Dow University of Health Sciences (DUHS), Karachi, Pakistan.
Moffitt Cancer Center, University of South Florida, Tampa, FL.
Medicine (Baltimore). 2024 Mar 8;103(10):e37331. doi: 10.1097/MD.0000000000037331.
Leukocyte parameters are predicted to be affected in patients with metabolic syndrome (MetS). We conducted a systematic review and meta-analysis to study the association between white blood cell parameters (WBC) in people with and without MetS.
PubMed, EMBASE, Scopus and Cochrane Library databases were searched according to the study protocol. The standardized mean difference (SMD) and 95% confidence intervals (CI) of leukocyte markers between individuals with and without MetS were pooled using an inverse variance model. Additionally, a subgroup analysis by sex was performed where possible. Methodological quality assessment was conducted using the Newcastle-Ottawa scale (NOS) for observational studies and the Cochrane Risk of Bias tool 2.0 for Randomized Controlled Trials (RCTs).
Of 6068 articles identified, 63 were eligible for the study. Compared to controls, individuals with MetS showed significantly higher concentrations of total leukocyte count (SMD [95% CI]: 0.60 [0.55-0.65]; P < .00001; I2 = 100%), neutrophil counts (0.32 [0.28-0.37]; P < .00001; I2 = 99%), lymphocyte counts (0.15 [0.07-0.23]; P = .0004; I2 = 100%), basophil counts (0.01 [0.00-0.02]; P = .02; I2 = 98%), monocyte counts (0.05 [0.02-0.09]; P = .003; I2 = 99%), and neutrophil-to-lymphocyte ratio (0.24 [0.15-0.33]; P < .00001; I2 = 98%). There were no significant differences in the eosinophil count (0.02 [-0.01 to 0.05]; P = .19; I2 = 96%) and monocyte-to-lymphocyte ratio (0.06 [-0.05 to 0.17]; P = .27; I2 = 100%) between patients with and without MetS, however, the lymphocyte-to-monocyte ratio (0.52 [-0.81 to -0.23]; P = .0005; I2 = 52%) tended to be significantly lower in patients with MetS.
Biomarkers such as total leukocyte count, neutrophil count, lymphocyte count, basophil count, monocyte count and neutrophil-to-lymphocyte ratio are associated with higher levels in patients in MetS and thus can potentially be used for early detection of MetS.
白细胞参数预计会受到代谢综合征(MetS)患者的影响。我们进行了一项系统综述和荟萃分析,以研究有和没有 MetS 的人群之间白细胞参数(WBC)的相关性。
根据研究方案,检索 PubMed、EMBASE、Scopus 和 Cochrane 图书馆数据库。使用逆方差模型对有和没有 MetS 的个体之间的白细胞标志物的标准化均数差(SMD)和 95%置信区间(CI)进行汇总。如果可能,还进行了按性别进行的亚组分析。使用纽卡斯尔-渥太华量表(NOS)对观察性研究进行方法学质量评估,使用 Cochrane 偏倚风险工具 2.0 对随机对照试验(RCT)进行评估。
在 6068 篇文章中,有 63 篇符合研究标准。与对照组相比,患有 MetS 的个体白细胞总数(SMD [95%CI]:0.60 [0.55-0.65];P <.00001;I2 = 100%)、中性粒细胞计数(0.32 [0.28-0.37];P <.00001;I2 = 99%)、淋巴细胞计数(0.15 [0.07-0.23];P =.0004;I2 = 100%)、嗜碱性粒细胞计数(0.01 [0.00-0.02];P =.02;I2 = 98%)、单核细胞计数(0.05 [0.02-0.09];P =.003;I2 = 99%)和中性粒细胞与淋巴细胞比值(0.24 [0.15-0.33];P <.00001;I2 = 98%)显著更高。然而,患者与无 MetS 患者之间的嗜酸性粒细胞计数(0.02 [-0.01 至 0.05];P =.19;I2 = 96%)和单核细胞与淋巴细胞比值(0.06 [-0.05 至 0.17];P =.27;I2 = 100%)没有显著差异,但是 MetS 患者的淋巴细胞与单核细胞比值(0.52 [-0.81 至 -0.23];P =.0005;I2 = 52%)往往显著更低。
白细胞计数、中性粒细胞计数、淋巴细胞计数、嗜碱性粒细胞计数、单核细胞计数和中性粒细胞与淋巴细胞比值等生物标志物与 MetS 患者的高水平相关,因此可能有助于早期发现 MetS。